Clinical Outcomes of Sentinel Cerebral Protection System Use During Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis.

Autor: Ndunda PM; Internal Medicine, University of Kansas School of Medicine - Wichita, 1010 N Kansas Street, Wichita, KS 67214, USA. Electronic address: pndunda@kumc.edu., Vindhyal MR; Internal Medicine, University of Kansas School of Medicine - Wichita, 1010 N Kansas Street, Wichita, KS 67214, USA., Muutu TM; Internal Medicine, University of Kansas School of Medicine - Wichita, 1010 N Kansas Street, Wichita, KS 67214, USA., Fanari Z; Internal Medicine, University of Kansas School of Medicine - Wichita, 1010 N Kansas Street, Wichita, KS 67214, USA; Heartland Cardiology/Wesley Medical Center, University of Kansas School of Medicine - Wichita, 551 N. Hillside, Suite 520, Wichita, KS 67214, USA.
Jazyk: angličtina
Zdroj: Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2020 Jun; Vol. 21 (6), pp. 717-722. Date of Electronic Publication: 2019 Apr 25.
DOI: 10.1016/j.carrev.2019.04.023
Abstrakt: Objective: To compare the clinical outcomes following transcatheter aortic valve replacement (TAVR) with and without the use of the Sentinel Cerebral Protection System (Sentinel CPS).
Background: Stroke occurs in 2-5% of patients at 30 days after TAVR and increases mortality >3 fold. The Sentinel CPS is the only FDA (Food and Drug Administration) approved cerebral embolic protection device.
Methods: The Cochrane Library, PubMed and Web of Science were searched for relevant studies for inclusion in the meta-analysis. Two authors independently screened and included studies comparing the clinical outcomes after TAVR with and without the Sentinel CPS. Risk of bias was assessed using the Cochrane tools (RoB2.0 and ROBINS-I).
Results: Four studies comparing 606 patients undergoing TAVR with Sentinel CPS to 724 without any embolic protection device were included. Sentinel CPS use was associated with lower rates of 30-day mortality [0.8% vs 2.7%; RR 0.34 (95% CI 0.12, 0.92) I 2  = 0%], 30-day symptomatic stroke [3.5% vs 6.1%; RR 0.51 (95% CI 0.29, 0.90) I 2  = 0] and major or life-threatening bleeding [3.3% vs 6.6%; RR 0.50 (0.26, 0.98) I 2  = 16%]. There was no significant difference between the two arms in the incidence of acute kidney injury [0.8% vs 1%; RR 0.85 (95% CI 0.22, 3.24) I 2  = 0%] and major vascular complications [5.1% vs 6%; RR 0.74 (0.33, 1.67) I 2  = 45%].
Conclusion: The results suggest that Sentinel CPS use in TAVR is associated with a lower risk of stroke, mortality and major or life-threatening bleeding at 30 days.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: